Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 240-566-8 | CAS number: 16499-88-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute toxicity: Oral
In an acute oral toxicity study in female rats, following the acute toxic class method in accordance with the OECD Guideline 425, the LD50 was established to be 175 mg/kg (Lemoncelli, 2014).
Acute toxicity: Inhalation
In addition to the oral route of exposure, for substances other than gases, the information mentioned under REACH section 8.5.2 to 8.5.3 shall be provided for at least one other exposure route (REACH Regulation, column 2 adaptation of Annex VIII). For this substance, the Regulation states that the study does not need to be conducted if the substance is classified as skin corrosive. Therefore, an acute inhalation toxicity study should not be performed.
Acute toxicity: Dermal
In addition to the oral route of exposure, for substances other than gases, the information mentioned under REACH section 8.5.2 to 8.5.3 shall be provided for at least one other exposure route (REACH Regulation, column 2 adaptation of Annex VIII). For this substance, the Regulation states that the study does not need to be conducted if the substance is classified as skin corrosive. Therefore, an acute dermal toxicity study should not be performed.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 26 February 2014 - 28 April 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- up-and-down procedure
- Limit test:
- no
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: 8291-11-20
- Expiration date of the lot/batch: 31 December 2014
- Purity: 99.3 wt%
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature, 19-26°C
- Stability under test conditions: Test article was not characterized for stability. The impact on the study was considered minimal since an expiration date of 31 December 2014 was provided and the study was conducted within that timeframe.
- Solubility and stability of the test substance in the solvent/vehicle: no data
- Reactivity of the test substance with the solvent/vehicle of the cell culture medium: no data
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing:
The test article was dosed as received for the dose level of 550 mg/kg. The specific gravity of 0.8466 g/mL as per the MSDS was factored into the dosing calculations for the dose level of 550 mg/kg. The dose levels of 55 mg/kg and 175 mg/kg were prepared by weighing out the appropriate amount of test article in a graduated cylinder. The vehicle was added to obtain the proper volume and placed on a stir plate for stirring. For all test article preparations at all dose levels, the stock bottle was inverted several times prior to dispensing. - Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories, Inc.
- Age at study initiation: ~9-14 weeks at start of dosing
Protocol deviation:
The protocol stated that the age range of the animals on study was to be 8-12 weeks. The actual ages of the following animals were out of the protocol range: animal 3855F was ~ 13 weeks, animal 3849 was ~13 weeks, and animal 3850 was ~ 14 weeks. This deviation was not of a magnitude to affect the outcome of the study since the animals were within the protocol stated overall body weight range of 150 - 300 g and were still considered healthy young adults.
- Weight at study initiation: 191 to 250 grams
Protocol deviation:
The protocol stated the body weight ranges for the animals should be ± 20% of the mean initial weight at the outset (Day 1) of the study. Animal 3850 was over 20% of the mean initial weight (body weight was 250 g) of the first animal dosed (3851) which weighed 204 g. This deviation had no impact on the outcome of the study since they were of small magnitude and the animals were just slightly outside of the 20% mean initial weight of the first animal dosed and were still within the overall protocol specified range and all animals were still considered young healthy adults.
- Fasting period before study: yes, animals were fasted overnight prior to dose administration (not longer than 24 hours). Food was returned to the animals 30 minutes (± 15 minutes) after dosing.
- Housing: Animals were housed - group housed by sex upon receipt, individually housed upon assignment to study in compliance with the National Research Council "Guide for the Care and Use of Laboratory Animals." Calvert is a USDA registered and fully AAALAC accredited facility. No other species were kept in the same room.
- Diet (e.g. ad libitum): All animals had access to Harlan Teklad Rodent Diet (certified) ad libitum, except during the fasting period
- Water (e.g. ad libitum): Water was available ad libitum, to each animal via an automatic watering device.
- Acclimation period: A minimum of five days prior to dosing
ENVIRONMENTAL CONDITIONS
- Temperature (°C):18 to 27°C
- Humidity (%): 8 to 88%
- Photoperiod (hrs dark / hrs light): 12 hours light/12 hours dark
Protocol deviations:
The protocol required the temperature range in the animal room to be 20-26°C and the relative humidity range to be 30-70%. The temperature range was 18-27°C and the humidity range was 8-88%. Humidity did not record from ~ 12:00 PM on 23 Feb 2014 to ~ 6:00 AM on 28 Feb 2014. These deviations were not of a magnitude or duration to have had an impact on the study since the animals' health was not affected. The temperature and humidity recorder malfunction was considered to have minimal impact on the study since the rooms within the immediate vicinity of the room where the study animals were housed did not experience a major shift from the normal room temperature/humidity ranges during the times that the humidity was not recorded.
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- DOSAGE PREPARATION (if unusual): The test article was dosed as received for the dose level of 550 mg/kg. The specific gravity of 0.8466 g/ml as per the MSDS was factored into the dosing calculations for the dose level of 550 mg/kg. The dose levels of 55 mg/kg and 175 mg/kg were prepared by weighing out the appropriate amount of test article in a graduated cylinder. The vehicle was added to obtain the proper volume and placed on a stir plate for stirring. For all test article preparations at all dose levels, the stock bottle was inverted several times prior to dispensing.
Dose volumes were 5 mL/kg (55 mg/kg and 175 mg/kg) and 0.65 mL/kg (550 mg/kg).
Method of study performance:
The first animal was dosed at an initial dose level of 550 mg/kg. Since the animal died, the second animal received 175 mg/kg. Since toxicity at the dose of 175 mg/kg resolved by Day 2, a dose level of 550 mg/kg was administered to an additional female rat. Mortality was observed at 550 mg/kg and dosing continued at a dose level of 175 mg/kg. Mortality was observed and dosing continued at a dose level of 55 mg/kg. Toxicity was not observed so dosing continued at 175 mg/kg. Mortality was observed at 175 mg/kg and dosing continued at 55 mg/kg. Since no mortality was observed at 55 mg/kg, dosing continued at 175 mg/kg. A total of 8 females were dosed. The test continued based on the fixed time interval outcomes of all the animals up to the point and until one of the stopping criteria was met. There were three possible stopping criteria.
- 3 consecutive animals servive at the limit dose;
- 5 reversals occur in any 6 consecutive animals tested;
- or at least 4 animals have followed
Dose progression and stopping criteria were calculated using a dedicated software program [Acute Oral Toxicity (Guideline 425) Statistical Program] provided by the EPA. - Doses:
- 55, 175 and 550 mg/kg
- No. of animals per sex per dose:
- 55 mg/kg: 2 female rats
175 mg/kg: 4 female rats
550 mg/kg: 2 female rats - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing:
Mortality/Morbidity: recorded once daily
Clinical observations: Clinical observations were collected manually. On the day of dosing (Day 1) animals were observed prior to dosing and approximately 30 minutes and 4 hours post-dose. Animals were observed once daily thereafter (Days 2-15).
Body weights - Animal weights were manually recorded prior to dosing on Day 1, and on Days 8 and 15 or upon death
- Necropsy of survivors performed: yes
All surviving rats were sacrificed by CO2 asphyxiation and a gross necropsy was performed at termination of the study and on animals 3851, 3853, 3854, 3849 when the animals were found dead.
The necropsy included examination of the external body surface, all orifices and the cranial, thoracic and abdominal cavities and their contents.
All abnormalities were described completely and recorded. At the completion of necropsy, carcasses were disposed of according to laboratories' SOP. - Statistics:
- The LD50 was calculated for the main test (when the data allowed) using the AOT425StatPgm developed by Westat May, 2001 (available via EPA website).
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 175 mg/kg bw
- Based on:
- test mat.
- Mortality:
- For the dose of 550 mg/kg: animals 3851 and 3853 were found dead 30 minutes post done.
For the dose of 175 mg/kg: animals 3854 and 3849 were found dead 30 minutes post done. No mortality was observed in the remaining two animals (3852 and 5798) that received this dose level.
For the dose of 55 mg/kg: no mortality was observed in any of the animals. - Clinical signs:
- other: Animal 3851F dosed at 550 mg/kg was found dead 30 minutes post dose. The next animal (3852F) was dosed at 175 mg/kg. At 30 minutes post dose, it exhibited abnormal gait and stance, tremors, and decreased body tone. At 4 hours post dose, only abnormal gait
- Gross pathology:
- Terminal necropsy revealed no visible lesions in the any of the animals receiving test article at 55 mg/kg. Necropsy of animal 3854 treated at 175 mg/kg that was found dead 30 minutes post dose on Day 1, revealed no visible lesions, test article visible in stomach. Necropsy of animal 3849 treated at 175 mg/kg that was found dead 30 minutes post dose on Day 1, revealed intestines dark red. Terminal necropsy of all other animals treated at 175 mg/kg revealed no visible lesions. Terminal necropsy of animal 3851 revealed no visible lesions. Necropsy of animal 3853 that was found dead 30 minutes post dose on Day 1 revealed intestines bright red.
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- Based on the results of this study, the estimated oral LD50 for Surfonamine MW 781 in rats is 175 mg/kg and is listed as a GHS Category 3 test article.
Surfonamine MW 781 is classified under HMIS as "2 (Moderately Toxic)", it is an EPA Category II test article, and is WHMIS Controlled: Class D - Toxic. An EEC Risk Phrase of R-25 - Toxic is required for Surfonamine MW 781.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 175 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- the study does not need to be conducted because the substance is classified as corrosive to the skin
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- other justification
- Justification for data waiving:
- the study does not need to be conducted because the substance is classified as corrosive to the skin
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute Oral Toxicity:
An acute oral toxicity study with Surfonamine MW 781 according to the acute toxic class method in female rats (OECD guideline 425) was performed (Lemoncelli, 2014). One animal dosed at 550 mg/kg was found dead 30 minutes post dose. Necropsy of animal 3851F revealed no visible lesions. The next animal was dosed at 175 mg/kg. At 30 minutes post dose, it exhibited abnormal gait and stance, tremors, and decreased body tone. At 4 hours post dose, only abnormal gait and stance was noted. From Days 2-15, the animal appeared normal. Terminal necropsy of one animal revealed no visible lesions. As per AOT425StatPgm, the next animal was dosed at 550 mg/kg. The animal was found dead at 30 minutes post dose. Necropsy revealed intestines bright red. The next animal was dosed at 175 mg/kg. The animal was found dead at 30 minutes post dose. Necropsy revealed no visible lesions, test article was visible in stomach. Following the dose of 175 mg/kg, a dose of 55 mg/kg was administered to one animal. The animal appeared normal from 30 minutes post dose through Day 15. One animal dosed at 175 mg/kg was found dead 30 minutes post dose. Necropsy revealed intestines dark red. The next animal was dosed at 55 mg/kg. From 30 minutes post dose through Day 15, it appeared normal. Terminal necropsy revealed no visible lesions. One animal dosed at 175 mg/kg exhibited decreased activity, body quivering, and abnormal gait and stance at 30 minutes post dose. At 4 hours post dose, decreased activity, body quivering, abnormal gait and stance, decreased body tone, and piloerection were observed. On Day 2, only piloerection and decreased body tone persisted in one animal. From Days 3- 15, one animal appeared normal. Terminal necropsy revealed no visible lesions. Based on the results of this study, the estimated oral LD50 for the test substance is 175 mg/kg.
Acute toxicity: Inhalation
In addition to the oral route of exposure, for substances other than gases, the information mentioned under REACH section 8.5.2 to 8.5.3 shall be provided for at least one other exposure route (REACH Regulation, column 2 adaptation of Annex VIII). For this substance, the Regulation states that the study does not need to be conducted if the substance is classified as skin corrosive. Therefore, an acute inhalation toxicity study should not be performed.
Acute toxicity: Dermal
In addition to the oral route of exposure, for substances other than gases, the information mentioned under REACH section 8.5.2 to 8.5.3 shall be provided for at least one other exposure route (REACH Regulation, column 2 adaptation of Annex VIII). For this substance, the Regulation states that the study does not need to be conducted if the substance is classified as skin corrosive. Therefore, an acute dermal toxicity study should not be performed
Justification for classification or non-classification
Acute Oral Classification:
Based on the results of this study, the estimated oral LD50 for the test substance in rats is 175 mg/kg and is listed as a GHS Category 3 test article.
Acute Inhalation Classification:
No data were available to decide on the classification for the inhalation route.
Acute Dermal Classification:
No data were available to decide on the classification for the dermal route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.